Novo Nordisk plans USD 2.3bn manufacturing expansion in Denmark
Novo Nordisk A/S is spending DKK 15.9bn (USD 2.29bn) to expand production facilities in Denmark as the obesity drug manufacturer looks to ensure capacity for its future portfolio.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.